Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|March 3, 2016
Dr. Jose P. Zevallos on Tobacco-Related Mutations in HPV-Positive Oropharyngeal SCC
Author(s)Jose P. Zevallos, MD, MPH, FACS
Zevallos says the study consisted of 66 patients and found that there were distinct genomic differences between HPV-positive smokers and non-smokers.
Advertisement
Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a recent study that looked at molecular profiles determined by targeted DNA sequencing of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC). The purpose of the study was to determine if patients with HPV-positive oropharyngeal SCC, who were also smokers, had a different mutational status than non-smokers.
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
4
Denosumab Biosimilar Approved For Existing Oncology Indications
5